search
Back to results

Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome

Primary Purpose

Carpal Tunnel Syndrome

Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
lidocaine patch 5%
Sponsored by
Endo Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Carpal Tunnel Syndrome focused on measuring lidocaine patch 5%, Lidoderm, carpal tunnel syndrome, pain, nerve compression injury, topical analgesic

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Are males or females 18 years of age or older Have confirmed diagnosis of CTS in one or both wrists. For patients with bilateral CTS, the most painful wrist will be identified as the "index" wrist, and will be the wrist used for all efficacy evaluations. Have clinical symptoms of pain, paresthesia, numbness and/or tingling in the distribution of the median nerve Have positive findings from electrodiagnostic tests using accepted criteria Have classification of the wrist(s) as "classic" or "probable" using the Katz Hand Diagram (Katz and Stirrat, 1990) Have worst daily pain intensity greater than 5 (0-10 scale) on approximately 75% of days over the previous 3 months; this criteria will be assessed at the screening visit only Have a normal 12-lead electrocardiogram (ECG) without any clinically significant abnormalities in heart rate, rhythm, or conduction Have been informed of the nature of the study and provided written informed consent Exclusion Criteria: Have a positive serum pregnancy test (females of childbearing potential only) Have tumors or cysts in the wrist, muscle wasting in the forearm and/or hand, peripheral neuropathy, mononeuropathy multiplex, or hand arthritis Have had previous CTS surgery Have severe CTS as defined by electrodiagnostic findings Have had steroid injections for CTS in the previous 3 months Have used diuretics (except a stable dose for hypertension) or Vitamin B6 or topical treatments for CTS (e.g., ultrasound, iontophoresis, cold laser) in the past 2 weeks Require sleep medications Are using a lidocaine-containing product that cannot be discontinued during the study Have a known sensitivity or allergy to an amide-type local anesthetic agent para-aminobenzoic (PABA) derivatives or local anesthetics Have previously participated in a Lidoderm study Have severe renal insufficiency (creatinine clearance of <30 mL/min) Have moderate or greater hepatic impairment, including a history of or active hepatitis Have abnormal clinical laboratory test results unless deemed clinically insignificant by the investigator Have current or planned litigation, or who are planning to acquire or are currently receiving Worker's Compensation or Social Security benefits, or who, in the opinion of the investigator, exhibit any evidence of secondary gain (monetary or non-monetary) associated with carpal tunnel syndrome pain. Have a history of alcohol or substance abuse within the last 3 years Have received an investigational drug or product or participated in an investigational drug study within a period of 30 days or 5 half-lives prior to receiving study drug

Sites / Locations

  • PPD

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Lidocaine Patch 5%

Placebo

Arm Description

1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.

1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.

Outcomes

Primary Outcome Measures

Worst daily pain intensity score

Secondary Outcome Measures

Average daily pain intensity score
Levine CTS Symptom Severity and Functional Status Scales
Mean interference with daily activities
Intensity of Various Pain Qualities
Quality of Sleep
Global Assessment of Treatment Satisfaction and Impression of Change

Full Information

First Posted
December 15, 2005
Last Updated
June 13, 2011
Sponsor
Endo Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00266214
Brief Title
Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome
Official Title
A Randomized, Double-Blind Study Comparing the Safety and Efficacy of the Lidocaine Patch 5% With Placebo in Patients With Pain From Carpal Tunnel Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
June 2011
Overall Recruitment Status
Terminated
Why Stopped
Sponsor decision
Study Start Date
November 2005 (undefined)
Primary Completion Date
January 2007 (Actual)
Study Completion Date
January 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Endo Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to evaluate the analgesic efficacy and safety of the lidocaine patch 5% compared to placebo in patients with moderate to severe pain associated with carpal tunnel syndrome.
Detailed Description
Patients with carpal tunnel syndrome (CTS)as determined by electrodiagnostic testing and moderate to severe pain will be randomized to receive either the lidocaine patch 5% or placebo patch q24h. The total duration of the double-blind treatment phase of the study will be 8 weeks. At baseline and at periodic visits to the clinic, patients will perform pain and functionality assessments. Patients with bilateral CTS will identify the "index" wrist (i.e., the more painful wrist), which will subsequently be the wrist used for all efficacy assessments throughout the study. Treatment Regimen and Route of Administration: Patients will apply one patch (either a lidocaine patch 5% or a matching placebo patch) to the volar aspect of each affected wrist once every 24 hours.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carpal Tunnel Syndrome
Keywords
lidocaine patch 5%, Lidoderm, carpal tunnel syndrome, pain, nerve compression injury, topical analgesic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
210 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lidocaine Patch 5%
Arm Type
Experimental
Arm Description
1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
Intervention Type
Drug
Intervention Name(s)
lidocaine patch 5%
Other Intervention Name(s)
Lidoderm
Intervention Description
1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
Primary Outcome Measure Information:
Title
Worst daily pain intensity score
Time Frame
Week 8
Secondary Outcome Measure Information:
Title
Average daily pain intensity score
Time Frame
Week 8
Title
Levine CTS Symptom Severity and Functional Status Scales
Time Frame
Week 8
Title
Mean interference with daily activities
Time Frame
Week 8
Title
Intensity of Various Pain Qualities
Time Frame
Week 8
Title
Quality of Sleep
Time Frame
Week 8
Title
Global Assessment of Treatment Satisfaction and Impression of Change
Time Frame
Week 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Are males or females 18 years of age or older Have confirmed diagnosis of CTS in one or both wrists. For patients with bilateral CTS, the most painful wrist will be identified as the "index" wrist, and will be the wrist used for all efficacy evaluations. Have clinical symptoms of pain, paresthesia, numbness and/or tingling in the distribution of the median nerve Have positive findings from electrodiagnostic tests using accepted criteria Have classification of the wrist(s) as "classic" or "probable" using the Katz Hand Diagram (Katz and Stirrat, 1990) Have worst daily pain intensity greater than 5 (0-10 scale) on approximately 75% of days over the previous 3 months; this criteria will be assessed at the screening visit only Have a normal 12-lead electrocardiogram (ECG) without any clinically significant abnormalities in heart rate, rhythm, or conduction Have been informed of the nature of the study and provided written informed consent Exclusion Criteria: Have a positive serum pregnancy test (females of childbearing potential only) Have tumors or cysts in the wrist, muscle wasting in the forearm and/or hand, peripheral neuropathy, mononeuropathy multiplex, or hand arthritis Have had previous CTS surgery Have severe CTS as defined by electrodiagnostic findings Have had steroid injections for CTS in the previous 3 months Have used diuretics (except a stable dose for hypertension) or Vitamin B6 or topical treatments for CTS (e.g., ultrasound, iontophoresis, cold laser) in the past 2 weeks Require sleep medications Are using a lidocaine-containing product that cannot be discontinued during the study Have a known sensitivity or allergy to an amide-type local anesthetic agent para-aminobenzoic (PABA) derivatives or local anesthetics Have previously participated in a Lidoderm study Have severe renal insufficiency (creatinine clearance of <30 mL/min) Have moderate or greater hepatic impairment, including a history of or active hepatitis Have abnormal clinical laboratory test results unless deemed clinically insignificant by the investigator Have current or planned litigation, or who are planning to acquire or are currently receiving Worker's Compensation or Social Security benefits, or who, in the opinion of the investigator, exhibit any evidence of secondary gain (monetary or non-monetary) associated with carpal tunnel syndrome pain. Have a history of alcohol or substance abuse within the last 3 years Have received an investigational drug or product or participated in an investigational drug study within a period of 30 days or 5 half-lives prior to receiving study drug
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
PPD
Organizational Affiliation
PPD
Official's Role
Study Director
Facility Information:
Facility Name
PPD
City
Austin
State/Province
Texas
ZIP/Postal Code
78704
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome

We'll reach out to this number within 24 hrs